Загрузка...
Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis
Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease. Dyslipidemia is a known adverse effect of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody used in RA treatment. We aimed to assess the effect of TCZ on lipid profile and adipokine levels in RA patient...
Сохранить в:
| Опубликовано в: : | Int J Mol Sci |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6770905/ https://ncbi.nlm.nih.gov/pubmed/31540528 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20184633 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|